header
Image from OpenLibrary

Gastroretentive system for delivering an antipsychotic drug / Shereen Hamdi Noshi ; Supervised Mahmoud M. Ghorab , Hussein O. Ammar

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Shereen Hamdi Noshi , 2015Description: 244 P. : charts , facsimiles ; 25cmOther title:
  • نظام لإستبقاء الأدوية المضادة للذهان فى المعدة [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics Summary: Schizophrenia is a severe and disabling mental illness. It affects approximately 1% of the population worldwide and it is a chronic, severe disorder, lacking curative treatment. The suicide rate is as high as 9 - 13%, with the incidence of suicide attempt reaching 50% of diagnosed patients over a lifetime. The onset of schizophrenia usually occurs around 18 - 25 years of age and is often preceded by premorbid behavioural deviations, such as social withdrawal and affective changes. The symptoms and severity can vary over individual with schizophrenia. The symptoms are commonly divided into three categories, namely, positive symptoms, negative symptoms and cognitive deficits. Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as {u2018}typical{u2019} antipsychotics) and second generation antipsychotics (SGAs, formerly known as {u2018}atypical{u2019} antipsychotics). First - generation antipsychotics are as effective as second - generation drugs in treating the 2positive3 symptoms of schizophrenia, such as hallucinations, delusions, and paranoia, although they vary in their propensity to cause side effects
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.Ph.D.2015.Sh.G (Browse shelf(Opens below)) Not for loan 01010110067472000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.Ph.D.2015.Sh.G (Browse shelf(Opens below)) 67472.CD Not for loan 01020110067472000

Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics

Schizophrenia is a severe and disabling mental illness. It affects approximately 1% of the population worldwide and it is a chronic, severe disorder, lacking curative treatment. The suicide rate is as high as 9 - 13%, with the incidence of suicide attempt reaching 50% of diagnosed patients over a lifetime. The onset of schizophrenia usually occurs around 18 - 25 years of age and is often preceded by premorbid behavioural deviations, such as social withdrawal and affective changes. The symptoms and severity can vary over individual with schizophrenia. The symptoms are commonly divided into three categories, namely, positive symptoms, negative symptoms and cognitive deficits. Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as {u2018}typical{u2019} antipsychotics) and second generation antipsychotics (SGAs, formerly known as {u2018}atypical{u2019} antipsychotics). First - generation antipsychotics are as effective as second - generation drugs in treating the 2positive3 symptoms of schizophrenia, such as hallucinations, delusions, and paranoia, although they vary in their propensity to cause side effects

Issued also as CD

There are no comments on this title.

to post a comment.